Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial.

Background/Objective: Optimal vitamin D levels are required for bone health and proper functionality of the nervous, musculoskeletal and immune systems. The objective of this study was to assess the efficacy and safety profiles of new weekly calcifediol formulations with the potential to improve adh...

Descripción completa

Detalles Bibliográficos
Publicado en:Nutrients Vol. 16; no. 22; pp. 3796 - 3810
Autores principales: Jódar-Gimeno, Esteban, Pérez-Castrillón, Jose Luis, Nociar, Ján, Lojka, Michal, Nikolov, Dimitar, Cereto-Castro, Fernando, Novković, Snežana, Tarantino, Umberto, Mehsen-Cetre, Nadia, Arranz, Paula, Ostalé, Cristina Martínez, García-Bea, Aintzane, Gilaberte, Inmaculada
Formato: research tables/charts randomized controlled trial Journal Article
Publicado: MDPI Nov2024
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=181204543&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 181204543
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        20726643
        B0TT
      jtl: Nutrients
      issn: 20726643
      maglogo: N
    pubinfo:
      dt: Nov2024
      vid: 16
      iid: 22
      pid: 97109
      pub: MDPI
    artinfo:
      ui:
        181204543
        181204543
        181204543
        10.3390/nu16223796
        181204543
      ppf: 3796
      ppct: 14
      formats:
      tig:
        atl: Efficacy and Safety of Weekly Calcifediol Formulations (75 and 100 µg) in Subjects with Vitamin D Deficiency: A Phase II/III Randomised Trial.
      aug:
        au:
          Jódar-Gimeno, Esteban
          Pérez-Castrillón, Jose Luis
          Nociar, Ján
          Lojka, Michal
          Nikolov, Dimitar
          Cereto-Castro, Fernando
          Novković, Snežana
          Tarantino, Umberto
          Mehsen-Cetre, Nadia
          Arranz, Paula
          Ostalé, Cristina Martínez
          García-Bea, Aintzane
          Gilaberte, Inmaculada
        affil: Department of Endocrinology and Nutrition, Quirónsalud Madrid University Hospital, 28223 Madrid, Spain
      sug:
        subj:
          Vitamin D Deficiency Drug Therapy
          Vitamin D Therapeutic Use
          Vitamin D Administration and Dosage
          Drug Efficacy Evaluation
          Patient Safety Evaluation
          Treatment Duration
          Medication Compliance
          Treatment Outcomes
          Human
          Female
          Male
          Adult
          Middle Age
          Aged
          Randomized Controlled Trials
          Random Assignment
          Control Group
          Multicenter Studies
          Double-Blind Studies
          Placebos
          Vitamin D Blood
          Comparative Studies
          Descriptive Statistics
          Funding Source
          Adult: 19-44 years
          Middle Aged: 45-64 years
          Aged: 65+ years
          Female
          Male
      ab: Background/Objective: Optimal vitamin D levels are required for bone health and proper functionality of the nervous, musculoskeletal and immune systems. The objective of this study was to assess the efficacy and safety profiles of new weekly calcifediol formulations with the potential to improve adherence and outcome. Methods: A Phase II-III, double-blind, randomized, multicentre trial (EudraCT 2020-001099-14 and NCT04735926). Subjects were randomized 2:2:1 to calcifediol 75 µg, 100 µg and placebo. 25(OH)D levels were measured at 4, 16, 24, 32 and 52 weeks. The main outcome was the percentage of subjects who achieved a response defined as 25(OH)D levels ≥20 ng/mL and/or ≥30 ng/mL at week 16. Results: 398 subjects (51.1 ± 15.96 years, 74.2% females, 98.7% Caucasian) with plasma 25(OH)D levels between 10 and 20 ng/mL were randomized. A total of 376 subjects completed 16 weeks of treatment, and 355 subjects completed the study. Six patients withdrew due to an adverse event, all unrelated to treatment. At week 16, 93.6% and 74.4% of subjects receiving calcifediol 75 µg achieved response levels of ≥20 ng/mL and ≥30 ng/mL, respectively. The calcifediol 100 µg group showed 98.7% and 89.9% of responders for ≥20 ng/mL and ≥30 ng/mL, respectively. Both calcifediol groups showed superiority over placebo at each response level at all time points analyzed (p < 0.0001). Calcifediol treatments increased 25(OH)D levels from baseline to week 24 and remained stable thereafter. The frequency of treatment-emergent adverse events was balanced between groups. Conclusions: New weekly calcifediol 75 and 100 µg formulations showed an effective and sustained response with a good long-term safety profile.
      pubtype: Academic Journal
      doctype:
        research
        tables/charts
        randomized controlled trial
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N